Table 5 Medical consultation 40 to 56 days after boost COVID-19 vaccination separated by gender
Female | Male | |||||
|---|---|---|---|---|---|---|
ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | |
(n = 205) | (n = 1189) | (n = 2865) | (n = 257) | (n = 448) | (n = 2133) | |
Medical consultation, thereof... | 33 (16.1%) | 233 (19.6%) | 533 (18.6%) | 36 (14%) | 53 (11.8%) | 261 (12.2%) |
Outpatient | ||||||
Yes | 32 (97.0%) | 205 (88.0%) | 453 (85.0%) | 29 (80.6%) | 42 (79.2%) | 213 (81.6%) |
Planned | 1 (3.0%) | 27 (11.6%) | 75 (14.1%) | 5 (13.9%) | 9 (17.0%) | 41 (15.7%) |
No | 0 (0%) | 1 (0.4%) | 5 (0.9%) | 2 (5.6%) | 2 (3.8%) | 7 (2.7%) |
Inpatient/Clinic | ||||||
Yes | 5 (15.2%) | 16 (6.9%) | 44 (8.3%) | 8 (22.2%) | 5 (9.4%) | 41 (15.7%) |
Planned | 0 (0%) | 2 (0.9%) | 5 (0.9%) | 1 (2.8%) | 0 (0%) | 4 (1.5%) |
No | 28 (84.8%) | 215 (92.3%) | 484 (90.8%) | 27 (75.0%) | 48 (90.6%) | 216 (82.8%) |
Pre-existing conditions | ||||||
Yes | 2 (6.1%) | 28 (12.0%) | 60 (11.3%) | 9 (25.0%) | 12 (22.6%) | 43 (16.5%) |
Partially | 10 (30.3%) | 85 (36.5%) | 217 (40.7%) | 12 (33.3%) | 10 (18.9%) | 73 (28.0%) |
No | 21 (63.6%) | 120 (51.5%) | 256 (48%) | 15 (41.7%) | 31 (58.5%) | 145 (55.6%) |
Suspected association to vaccination | ||||||
Yes | 1 (3%) | 16 (6.9%) | 26 (4.9%) | 2 (5.6%) | 0 (0%) | 10 (3.8%) |
Partially | 4 (12.1%) | 49 (21%) | 118 (22.1%) | 6 (16.7%) | 11 (20.8%) | 53 (20.3%) |
No | 28 (84.8%) | 168 (72.1%) | 389 (73%) | 28 (77.8%) | 42 (79.2%) | 198 (75.9%) |